Fig 1: PP2A and CDK16 regulate autophagosome biogenesis and WIPI2B puncta formation(A–E) Representative merged micrographs of distal axonal tips of GFP-LC3B DRG neurons ectopically expressing SNAP-WIPI2B and Halo-B55α (A), Halo-Β55δ (B), Halo-CDK16 (C), Halo-CDK17 (D), or Halo-CDK18 (E). White arrowheads indicate the colocalization event depicted in the magnified views and quantified in the corresponding line scan plot below the full micrograph. Borders of the magnified views and color of lines in the line scan plot denote the channel: GFP-LC3B (green), Halo-B55α/δ or Halo-CDK16/17/18 (red), SNAP-WIPI2B (blue). Scale bars: 2 μm.(F) Representative micrographs of SNAP-WIPI2B in the distal axonal tip of GFP-LC3B DRG neurons ectopically expressing SNAP-WIPI2B and Halo-B55α (left) or Halo-CDK16 (right). Scale bars: 2 μm.(G) Quantification of SNAP-WIPI2B puncta in the distal axonal tip of GFP-LC3B DRG neurons ectopically expressing SNAP-WIPI2B and Halo-B55α, Halo-B55δ, Halo-CDK16, Halo-CDK17, or Halo-CDK18 (violin plot, median + first and third quartiles; n ≥ 31 across three biological replicates for each condition). Unmarked comparisons are not significant (p > 0.05), ∗∗∗∗p ≤ 0.0001 by Ordinary one-way ANOVA with Holm-Sidak’s multiple comparisons test.(H) Representative time-lapse micrographs of GFP-LC3B in the distal axonal tip of DRG neurons depicting an autophagosome biogenesis event (white arrowhead). Scale bars: 2 μm.(I) Quantification of the rate of AV biogenesis (GFP-LC3B puncta) in DRG neurons ectopically expressing SNAP-WIPI2B and Halo-B55α, Halo-B55δ, Halo-CDK16, Halo-CDK17, or Halo-CDK18 (mean +SEM; n for each condition is indicated on the bottom of each bar and represents total n across three biological replicates). Unmarked comparisons are not significant (p > 0.05), ∗∗∗p ≤ 0.001, ∗p ≤ 0.05 by Ordinary one-way ANOVA with Holm-Sidak’s multiple comparisons test.(J) Representative micrographs of SNAP-WIPI2B, SNAP-WIPI2B (S395A), and SNAP-WIPI2B (S395E) in the distal axonal tip of GFP-LC3B DRG neurons ectopically expressing the indicated SNAP construct and Halo-CDK16. Scale bars: 2 μm.(K) Quantification of WIPI2B puncta in the distal axonal tip of GFP-LC3B DRG neurons expressing SNAP-WIPI2B, SNAP-WIPI2B(S395A), or SNAP-WIPI2B(S395E) along with Halo-CDK16 (violin plot, median + first and third quartiles; n ≥ 37 across three biological replicates for each condition). Unmarked comparison is not significant (p > 0.05), ∗∗p ≤ 0.01 by Kruskal-Wallis test with Dunn’s multiple comparisons test.(L) Quantification of the rate of AV biogenesis (GFP-LC3B puncta) in DRG neurons ectopically expressing SNAP-WIPI2B, SNAP-WIPI2B (S395A), or SNAP-WIPI2B (S395E) along with Halo-CDK16 (mean +SEM; n for each condition is indicated on the bottom of each bar and represents total n across three biological replicates). Unmarked comparison is not significant (p > 0.05), ∗p ≤ 0.05 by Kruskal-Wallis test with Dunn’s multiple comparisons test.(M) Quantification of the rate of AV biogenesis (GFP-LC3B puncta) in DRG neurons treated with control, B55α, B55δ, or CDK16 siRNA (mean + SEM; n for each condition is indicated on the bottom of each bar and represents total n across three biological replicates). Unmarked comparisons are not significant (p > 0.05), ∗∗p ≤ 0.01, ∗p ≤ 0.05 by Kruskal-Wallis test with Dunn’s multiple comparisons test.
Fig 2: Mammalian PP2A dephosphorylates WIPI2B tail in vitro(A) Schematic of the GST- and HA-tagged WIPI2B tail peptide containing the last 78 amino acids of human WIPI2B (amino acids 358–436). The S395 phosphorylation site is indicated in violet.(B) Representative immunoblots of the in vitro dephosphorylation assay with purified WIPI2B tail and phosphorylated WIPI2B tail, with and without recombinant human PP2A.(C) Quantification of phosphoWIPI2B signal relative to total WIPI2B signal for the in vitro dephosphorylation assay represented in B (mean ± SEM, n = 3). ∗∗∗p ≤ 0.001, ∗∗p ≤ 0.01, ns p > 0.05 by one-way ANOVA with Tukey’s multiple comparisons test.
Fig 3: PPP1R17 inhibits PP2A phosphatase activity in CD. (A) AlphaFold Multimer modeling predicting binding of human PPP1R17 to PP2Ac subunit. (B) Representative PLA in margin (Left) versus CD adenoma core (Right) using antibodies for PP2Ac and PPP1R17. Red puncta indicate peptides in proximity. (C) MoMo motif analysis of preferentially hyperphosphorylated and dephosphorylated motifs in CD adenoma core versus margin (n = 3/group; Top panel) or in mCortPPP1R17 versus mCortGFP cells (n = 5/group; Bottom panel). (D) Representative multiplexed immunohistochemistry staining of a CD adenoma (P17) and its adjacent margin. Inset identifies the region of interest that is magnified to demonstrate pERK and pAKT at the margin of core and margin. (E) Western blots of mCort cells and AtT-20 cells transiently transfected with lentiviral plasmids encoding PPP1R17 versus GFP evaluating phosphorylation of PP2A targets AKT, ERK, and S6. (n = 3/condition; bar graphs with t tests; *P < 0.05; **P < 0.01; blank–not significant).
Supplier Page from Abcam for Recombinant human PPP2R1A + PP2A-alpha protein (Active) (6x His tag N-Terminus, GST tag N-Terminus)